ArticleThe Journal of experimental medicine2015
Adenosine signaling promotes hematopoietic stem and progenitor cell emergence.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 85 citations in OpenAlex.
- Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells.Clinical and translational science · 2025Article
- 'Nomadic' Hematopoietic Stem Cells Navigate the Embryonic Landscape.Stem cell reviews and reports · 2025Review
- ADA2 regulates inflammation and hematopoietic stem cell emergence via the ACommunications biology · 2024Article
- Haematopoietic development and HSC formation in vitro: promise and limitations of gastruloid models.Emerging topics in life sciences · 2023Review
- Glia maturation factor-γ is required for initiation and maintenance of hematopoietic stem and progenitor cells.Stem cell research & therapy · 2023Article
- De Novo Generation of Human Hematopoietic Stem Cells from Pluripotent Stem Cells for Cellular Therapy.Cells · 2023Review
- In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies.Oncoimmunology · 2023Article
- Purinergic Signaling and Its Role in Mobilization of Bone Marrow Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Learning from Zebrafish Hematopoiesis.Advances in experimental medicine and biology · 2023Review
- Extracellular Adenosine (eAdo) - AStem cell reviews and reports · 2022Article
- Control of Directed Cell Migration after Tubular Cell Injury by Nucleotide Signaling.International journal of molecular sciences · 2022Article
- Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.MedComm · 2022Review
- Pyruvate metabolism guides definitive lineage specification during hematopoietic emergence.EMBO reports · 2022Article
- Zebrafish models of inflammation in hematopoietic development and disease.Frontiers in cell and developmental biology · 2022Review
- The immunomodulatory function of adenosine in sepsis.Frontiers in immunology · 2022Review
- The onset of circulation triggers a metabolic switch required for endothelial to hematopoietic transition.Cell reports · 2021Article
- Making Blood from the Vessel: Extrinsic and Environmental Cues Guiding the Endothelial-to-Hematopoietic Transition.Life (Basel, Switzerland) · 2021Review
- Regulation of Hemogenic Endothelial Cell Development and Function.Annual review of physiology · 2021Review
- Inflammasomes and the Maintenance of Hematopoietic Homeostasis: New Perspectives and Opportunities.Molecules (Basel, Switzerland) · 2021Review
- The Use of Induced Pluripotent Stem Cells to Study the Effects of Adenosine Deaminase Deficiency on Human Neutrophil Development.Frontiers in immunology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 6 institutions in 1 country.
Lili JingStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Owen J TamplinStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Michael J ChenStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Qing DengDepartment of Medical Microbiology and Immunology and Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706 Department of Medical Microbiology and Immunology and Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706.
Shenia PattersonDepartment of Medicine, Boston University School of Medicine and the Evans Center for Interdisciplinary Biomedical Research, Boston, MA 02118.
Peter G KimStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Ellen M DurandStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Ashley McNeilStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Julie M GreenDepartment of Medical Microbiology and Immunology and Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706 Department of Medical Microbiology and Immunology and Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706.
Shinobu MatsuuraDepartment of Medicine, Boston University School of Medicine and the Evans Center for Interdisciplinary Biomedical Research, Boston, MA 02118.
Julien AblainStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Margot K BrandtStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Thorsten M SchlaegerStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Anna HuttenlocherDepartment of Medical Microbiology and Immunology and Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706 Department of Medical Microbiology and Immunology and Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706.
George Q DaleyStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.
Katya RavidDepartment of Medicine, Boston University School of Medicine and the Evans Center for Interdisciplinary Biomedical Research, Boston, MA 02118.
Leonard I ZonStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138 Harvard Stem Cell Institute, Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138 zon@enders.tch.harvard.edu.
Boston Children's Hospital · USDana-Farber Cancer Institute · USBoston University · USUniversity of Wisconsin–Madison · USHarvard Stem Cell Institute · USHarvard University · US
Funding
TRANSCRIPTION FACTOR GATA-1 IN TERMINAL ERYTHROID DEVELOPMENTP01HL032262 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2021
$38.9MCORE--ZEBRAFISHP30DK049216 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ZHOU, YI · 1999 to 2015
$14.3MCustomized stem cells for clinical application in blood disordersR24DK092760 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI COLLINS, JAMES J, DALEY, GEORGE Q · 2011 to 2018
$10.7MEMBRYONIC HEMATOPOIESISR01HL048801 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1992 to 2016
$5.7MCOMPARATIVE APPROACH TO GLOBIN REGULATION/THALASSEMIAR01DK053298 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1998 to 2012
$3.9MMechanisms Regulating Megakaryocyte EndomitosisR01HL080442 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2006 to 2015
$3.6MTraining Program in Cardiovascular Biology: Pre-DoctoralT32HL007969 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2003 to 2019
$3.2MAdenosine Receptors and AtherogenesisR01HL093149 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2009 to 2012
$1.6MHoward Hughes Medical InstituteNHLBI NIH HHS 5U01 HL10001-05NHLBI NIH HHS HL007969NHLBI NIH HHS HL93149NHLBI NIH HHS P015PO1HL32262-32NHLBI NIH HHS P01 HL032262NHLBI NIH HHS R01 HL048801NHLBI NIH HHS R01 HL04880-21NHLBI NIH HHS R01 HL080442NHLBI NIH HHS R01 HL093149NHLBI NIH HHS T32 HL007969NIDDK NIH HHS 5P30 DK49216NIDDK NIH HHS 5R01 DK53298NIDDK NIH HHS P30 DK049216NIDDK NIH HHS R01 DK053298NIDDK NIH HHS R24 DK092760
Abstract
Hematopoietic stem cells (HSCs) emerge from aortic endothelium via the endothelial-to-hematopoietic transition (EHT). The molecular mechanisms that initiate and regulate EHT remain poorly understood. Here, we show that adenosine signaling regulates hematopoietic stem and progenitor cell (HSPC) development in zebrafish embryos. The adenosine receptor A2b is expressed in the vascular endothelium before HSPC emergence. Elevated adenosine levels increased runx1(+)/cmyb(+) HSPCs in the dorsal aorta, whereas blocking the adenosine pathway decreased HSPCs. Knockdown of A2b adenosine receptor disrupted scl(+) hemogenic vascular endothelium and the subsequent EHT process. A2b adenosine receptor activation induced CXCL8 via cAMP-protein kinase A (PKA) and mediated hematopoiesis. We further show that adenosine increased multipotent progenitors in a mouse embryonic stem cell colony-forming assay and in embryonic day 10.5 aorta-gonad-mesonephros explants. Our results demonstrate that adenosine signaling plays an evolutionary conserved role in the first steps of HSPC formation in vertebrates.
Indexed as
AdenosineAnimalsAortaEmbryonic Stem CellsEndothelium, VascularHematopoietic Stem CellsHumansInterleukin-8MiceMice, KnockoutMultipotent Stem CellsReceptor, Adenosine A2BAdenosineCXCL8 protein, humanInterleukin-8Receptor, Adenosine A2B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.